EGFR and colorectal carcinoma: TAS-102 plus bevacizumab is recommended as one of the standard treatment options in metastatic CRC patients that have progressed following first- and second-line therapies involving 5-FU plus oxaliplatin or irinotecan along with anti-EGFR or VEGFR therapies when excluding biomarker-directed and immunotherapy.